(Q38095232)

28 August 2017

title

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review (English)

1 reference

bilirubin metabolic disorder

28 August 2017

main subject

1 reference

1 reference

1 reference

Celia L Culley

1

1 reference

28 August 2017

Tony K L Kiang

series ordinal

2

1 reference

28 August 2017

Samuel E Gilchrist

series ordinal

3

1 reference

28 August 2017

Mary H H Ensom

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

2 April 2013

1 reference

Annals of Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

47

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

561-572

1 reference

HLA-B*5701 screening for hypersensitivity to abacavir

28 August 2017

cites work

1 reference

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

21 January 2018

1 reference

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study

21 January 2018

1 reference

Diagnostic tests 2: Predictive values

21 January 2018

1 reference

Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency

21 January 2018

1 reference

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency

21 January 2018

1 reference

Grey literature in meta-analyses

21 January 2018

1 reference

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

21 January 2018

1 reference

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R550

1 reference

28 August 2017

1 reference